Evidence map›Paper›PMID 32677988›Full record

ArticleBMC infectious diseases2020

External quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in primary laboratories in Germany.

Regina Selb, Klaus Jansen, Matthias Eckardt, Thalea Tamminga, Sandra Dudareva, Martyna Gassowski, Ingeborg Graeber, Eva Guhl, Dagmar Heuer, Susanne Buder and 1 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Regina SelbDepartment of Infectious Diseases, Unit for Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Seestrasse 10, 13353, Berlin, Germany. SelbR@rki.de.ORCID http://orcid.org/0000-0001-5531-5198
Klaus JansenDepartment of Infectious Disease Epidemiology, Unit for HIV/AIDS, STI and Blood-borne Infections, Robert Koch-Institute, Berlin, Germany.
Matthias EckardtDepartment of Infectious Diseases, Postgraduate Training for Applied Epidemiology (PAE), Robert Koch-Institute, Berlin, Germany.
Thalea TammingaDepartment of Infectious Disease Epidemiology, Unit for HIV/AIDS, STI and Blood-borne Infections, Robert Koch-Institute, Berlin, Germany.
Sandra DudarevaDepartment of Infectious Disease Epidemiology, Unit for HIV/AIDS, STI and Blood-borne Infections, Robert Koch-Institute, Berlin, Germany.
Martyna GassowskiDepartment of Infectious Diseases, Postgraduate Training for Applied Epidemiology (PAE), Robert Koch-Institute, Berlin, Germany.
Ingeborg GraeberDepartment of Dermatology and Venerology, German Reference Laboratory for Gonococci, Vivantes Hospital Berlin Neukölln, Berlin, Germany.
Eva GuhlDepartment of Dermatology and Venerology, German Reference Laboratory for Gonococci, Vivantes Hospital Berlin Neukölln, Berlin, Germany.
Dagmar HeuerDepartment of Infectious Diseases, Unit for Sexually Transmitted Bacterial Infections, Robert Koch-Institute, Berlin, Germany.
Susanne BuderDepartment of Dermatology and Venerology, German Reference Laboratory for Gonococci, Vivantes Hospital Berlin Neukölln, Berlin, Germany.
GORENET EQA study group

Funding

Bundesministerium für Gesundheit AZ ZMVI1-2516AUK700
6 · The paper itself

Abstract

backgroundWorldwide, an increase in antimicrobial resistance (AMR) of Neisseria gonorrhoeae has been observed. Until now, no protocol for an external quality assessment (EQA) has been available for Germany. The German gonococcal resistance network (GORENET) performed an EQA of primary laboratories in Germany in order to assess quality of antibiotic susceptibility testing, to gain information about laboratory procedures and to assess the impact of these procedures on test results.

methodsLaboratories assessed drug susceptibility to cefixime, ceftriaxone, azithromycin, penicillin and ciprofloxacin for five N. gonorrhoeae strains, using their standard laboratory protocols. Minimal inhibitory concentrations (MICs) were compared to World Health Organisation (WHO) consensus results (or, if not available, reference laboratory results), while deviation by +/- one doubling dilution was accepted. Data on laboratory procedures were collected via a standardised questionnaire. Generalized linear models and conditional inference trees (CTREE) were used to assess relationships between laboratory procedures and testing outcomes.

resultsTwenty-one primary laboratories participated in the EQA in June 2018. 96% of ciprofloxacin MICs were reported within accepted deviations, as well as 88% for cefixime, 85% for ceftriaxone, 79% for penicillin and 70% for azithromycin. The use of interpretation standards and general laboratory procedures like agar base, incubation settings or the use of control strains strongly differed between laboratories. In statistical analysis, incubation time of cultures < 24 h was associated with correct measurements. Additionally, a 5% CO

conclusionsIn conclusion, we report the development of a protocol for N. gonorrhoeae antimicrobial susceptibility testing in Germany. While testing results were in accordance with the expected consensus results in 70-96%, depending on the antibiotic agent, laboratory methodology was heterogeneous and may significantly affect the testing quality. We therefore recommend the development of a standard operating procedure (SOP) for N. gonorrhoeae susceptibility testing in Germany.

Indexed as

Laboratory Proficiency TestingAnti-Bacterial AgentsAzithromycinCefiximeCeftriaxoneCiprofloxacinDrug Resistance, BacterialGermanyGonorrheaHumansLaboratoriesMicrobial Sensitivity TestsNeisseria gonorrhoeaePenicillinsQuality ControlReference StandardsAnti-Bacterial AgentsAzithromycinCefiximeCeftriaxoneCiprofloxacinPenicillinsAMRAntimicrobial resistanceEQANeisseria gonorrhoeaeSusceptibility testing

Identifiers

PMID32677988
PMCPMC7366306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.